Hydrated crystalline forms of N- [3-fluoro-4-({6-(methyloxy)-7-[(3morpholin-4-ylpropyl)oxy]- quinolin-4-yl}oxy)phenyl] -N'-(4fluorophenyl)cyclopropane-1,1-dicarboxamide

Details for Australian Patent Application No. 2011224203 (hide)

Owner Exelixis, Inc

Inventors Cannon, Hilary; Kang, Feirong; Vogt, Frederick G.

Agent A J Park

Pub. Number AU-A-2011224203

PCT Pub. Number WO2011/112896

Priority 61/313,192 12.03.10 US

Filing date 11 March 2011

Wipo publication date 15 September 2011

International Classifications

C07D 215/22 Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

A61K 31/47 - Quinolines

A61P 35/00 Antineoplastic agents

Event Publications

4 October 2012 PCT application entered the National Phase

  PCT publication WO2011/112896 Priority application(s): WO2011/112896

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011224207-Intravenous formulations of Coenzyme Q10 (CoQ10) and methods of use thereof

2011224190-Query model over information as a networked service